The stock will trade on Phase 2 execution milestones rather than financial results. Key catalysts to monitor: first patient enrollment in ASCENTRA-UC (expected 2H 2026), IND submission for ASCENTRA-CD (2H 2026), and any early efficacy signals from the Phase 2 program. The $125M cash runway removes near-term financing risk but the pre-revenue profile means binary Phase 2 readout risk dominates.
Drug in focus
PALI drug pipeline →PALI-2108
● Neutral Named in this 8-K- Impact
- Phase
- Phase 2b
- Time to market
- If Phase 2b succeeds, PALI-2108 would need to advance to Phase 3 trials and then file for FDA approval, a process that typically takes several more years. The earliest potential approval would likely be 2029-2030 at the earliest, assuming successful trials.
- Next catalyst
- None dated
What to watchThe next major catalyst is the Phase 2b ASCENTRA-UC topline data expected in Q4 2027, roughly 12 months away. Positive data would validate PALI-2108's differentiated gut-targeted PDE4 approach in a large, well-controlled study; negative or mixed results would severely impact the stock since PALI-2108 is the company's only clinical-stage asset. Interim milestones to watch include ASCENTRA-CD (Crohn's) first patient dosing targeted for Q1 2027 and any early data presentations at medical conferences.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 11 $2.14entry
- T+1 · 3mo ago −8.41%α −8.66% · $1.96
- T+5 · 3mo ago −4.67%α −4.27% · $2.04
- T+20 · 2mo ago −4.21%α −3.15% · $2.05
- T+60 · 13d ago −41.59%α −41.10% · $1.25
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Palisade Bio reported Q2 2026 results in line with Street consensus (EPS -$0.05 vs -$0.05 est), with no revenue surprise. The filing is dominated by operational progress, FDA IND clearance, Phase 2 ASCENTRA-UC trial commencement expected in 2H 2026, and a strong $125.2M cash position funding through key Phase 2 readouts in 2027-2028. The $0.5M milestone license revenue from Newsoara is a modest positive, but the pre-revenue clinical-stage nature of the company makes this a pipeline-progress update rather than a financial catalyst.
Key Financial Metrics
Key Facts
- Net loss of $10.6M ($0.05/share) for Q2 2026 vs $2.8M ($0.58/share) in Q2 2025
- Cash and cash equivalents of $125.2M as of June 30, 2026, down from $133.4M at Dec 31, 2025
- FDA clearance of IND for Phase 2 ASCENTRA-UC trial of PALI-2108 received; enrollment expected 2H 2026
- Phase 2 UC primary efficacy readout expected 2H 2027; Phase 2 CD IND expected 2H 2026
- Recognized $0.5M license revenue milestone from Newsoara co-development agreement
- Phase 1 data showed 5/5 UC patients achieved clinical response, 2/5 clinical remission; FSCD cohort showed ~47.5% mean SES-CD reduction
Financial Impact
Net loss widened to $10.6M from $2.8M YoY driven by increased R&D ($7.4M vs $1.7M) and G&A ($4.8M vs $1.2M) expenses as the company scales for Phase 2. Cash burn of $8.2M in H1 2026 vs $4.4M in H1 2025. $125.2M cash runway sufficient through Phase 2 readouts.
Risk Factors
- Phase 2 trial failure or disappointing efficacy data
- Competition from approved IBD therapies (JAK inhibitors, anti-integrins, IL-23 inhibitors)
- Dilution risk if additional capital needed before Phase 2 readouts
- Small Phase 1 sample size (n=5 per cohort) may not predict Phase 2 results
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001357459-26-000017 |
| Document: pali-20260810.htm | 0001357459-26-000017 |
| Document: 0001357459-26-000017-index-headers.html | 0001357459-26-000017 |
| Document: 0001357459-26-000017-index.html | 0001357459-26-000017 |
| Document: 0001357459-26-000017.txt | 0001357459-26-000017 |
| 8-K Data (Synthetic) | 0001357459-26-000017 |
Track record
14 reports on PALI
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.08 Now $1.03 −4.19% settles Dec 15
- Nov 10, 20266d ago 8-K Neutral 5/10 Entry $1.17 Now $1.03 −11.97% settles Dec 10
- Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $1.13 Now $1.03 −8.85% settles Dec 9
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $1.16 Now $1.03 −11.21% settles Nov 30
- Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $1.69 to $1.43 Now $1.03 −39.05% ▼ −15.38% −14.82% vs SPY
- Sep 22, 20267w ago Press Release Bullish 6/10 Entry $1.69 to $1.43 Now $1.03 −39.05% ▼ −15.38% −14.82% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 Viewing Entry $2.14 to $2.05 Now $1.03 −51.87% ▼ −4.21% −3.15% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $1.89 to $2.10 Now $1.03 −45.50% ▲ +11.11% +7.93% vs SPY
- Jul 8, 202618w ago Insider Cluster Neutral 3/10 Entry $1.97 to $2.09 Now $1.03 −47.72% ▲ +6.09% +3.85% vs SPY
- Jun 11, 202622w ago 8-K Neutral 4/10 Entry $1.71 to $1.96 Now $1.03 −39.77% ▲ +14.62% +12.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers